

# Modern Mass Spectrometry-Based Platforms Solving Complex Biological Question

## Epigenetics and Cancer - Histone Modifications

*Samples – Preparation – Separation – Mass Spec Analysis – Informatics – Reporting*




*Archive Presentation – November 2011*

*Basic Histone Epiproteomics Assays*


**Jeremiah D. Tipton, Ph.D.**

Director and Applications Manager  
Applied Omics & Life Sciences LLC  
Agilent Technologies Applications Contractor

# Epigenetics and Cancer - Histone Modifications



Histone Acetyl Transferase (HAT)  
Histone Deacetylase (HDAC)  
Histone Methyltransferase






# Epigenetics and Cancer - Histone Modifications

(2011)


Type of Modification	H3K4	H3K9	H3K14	H3K27	H3K79	H3K20	H2BK5
Mono-methylation	activation	activation		activation	activation	activation	activation
Di-methylation		repression		repression	activation		
Tri-methylation	activation	repression		repression	repression		repression
Acetylation		activation	activation				




# Epigenetics and Cancer - Histone Modifications




H4 PTM Dynamics During Cell Cycle




Characterization of H2A Gene Family Members



## The Nucleosome



# Histone LCMS - QqQ Assay - Basic Assay




Bottom up

Trypsin  
Digestion

Other Common Strategies Developed – Glu C /Asp N/Arg C and chemical derivatization.



# Histone LCMS - QqQ Assay - Basic Assay



K4 Peptide / K9 K14 Peptide / K18 Peptide / K27 K36 Peptide / K 56 Peptide / K79 Peptide

Archive Original - November 29, 2011



# Histone LCMS - QqQ Assay - Basic Assay Assay Development – “K9-K14” Peptide

<p>*255.170 me1 K S T G G K A P R (2+) 542.3115 829.453</p>	<p>(2+) 535.3063</p>	<p>255.170 me1 K S T G G K A P R ac 815.442</p>
<p>213.158 me2 K S T G G K A P R x 521.3055 829.453</p>	<p>514.3004</p>	<p>213.158 me2 K S T G G K A P R ac 815.442</p>
<p>*227.175 me3 K S T G G K A P R x 528.3140 829.453</p>	<p>521.3089</p>	<p>227.175 me3 K S T G G K A P R ac 815.442</p>
<p>*227.175 ac K S T G G K A P R x 528.2985 829.453</p>	<p>521.2934</p>	<p>227.175 ac K S T G G K A P R ac 815.442</p>
<p>*241.145 x K S T G G K A P R x 535.3036 829.453</p>	<p>528.2985</p>	<p>241.145 x K S T G G K A P R ac 829.442</p>

# Histone LCMS - QqQ Assay - Basic Assay Assay Development – “K9-K14” Peptide

Add signal response for all K9/K14 peptides  
(Response in the peak area)

Divide the individual peak area by the total area  
(Result is the Percent Relative Occupancy )


Final Result is a ‘Digital Western Blot ‘






# Histone LCMS - QqQ Assay - Basic Assay


## Technical Note and Understanding



**K9 me3**




**K9 ac**




# Histone LCMS - QqQ Assay - Basic Assay - Results

Percent Relative Occupancy (% R.O.)

## Digital Western Blot CLL Samples




# Histone LCMS - QqQ Assay - Basic Assay - Results



Patient 1 (Sample 1)



Patient 2



Patient 1 (Sample 2)


Reference for "Heat Map"  
Patient Sample - HeLa S3

Delta %R.O.	(-) regulation	(+) regulation
0 - 2%	0-2%	0-2%
2 - 5%	2-5%	2-5%
5 - 10%	5-10%	5-10%
10+ %	10+%	5-10%

Data from Oncology Samples




# Histone LCMS - QqQ Assay - Basic Assay - Results



# Histone LCMS - QqQ Assay - Basic Assay - Results

Percent Relative Occupancy (% R.O.)




Decrease Inhibitor


# Histone LCMS - QqQ Assay - Basic Assay - Results

## Oncology Samples

Percent Relative Occupancy (% R.O.)



2-5 % Coefficient of Variance Between Technical Triplicates



~ 5% Difference Between Biological Reps

~ 10 - 15% Difference Between Grade II and IV Cells

# Epigenetics and Cancer - Histone Modifications

*Samples – Preparation – Separation – Mass Spec Analysis – Informatics – Reporting*

*Archive Presentation – November 2011*

*Basic Histone Epiproteomics Assays*

## Histone LCMS - QqQ Assay - Basic Assay

